Role of Medical Imaging in Cancers

Edited by
March 2021
228 pages
  • ISBN978-3-0365-0206-9 (Hardback)
  • ISBN978-3-0365-0207-6 (PDF)

This book is a reprint of the Special Issue Role of Medical Imaging in Cancers that was published in

This book is part of the book set Role of Medical Imaging in Cancers

Biology & Life Sciences
Medicine & Pharmacology

The issue of Cancers Journal entitled “Role of Medical Imaging in Cancers” presents a detailed summary of evidences about molecular imaging, including the role of computed tomography (CT), magnetic resonance imaging (MRI), single photon emission tomography (SPET) and positron emission tomography (PET) or PET/CT or PET/MR imaging in many type of tumors (i.e. sarcoma, prostate, breast and others), motivating the role of these imaging modalities in different setting of disease and showing the recent developments, in terms of radiopharmaceuticals, software and artificial intelligence in this field. The collection of articles is very useful for many specialists, because it has been conceived for a multidisciplinary point of view, in order to drive to a personalized medicine.

  • Hardback
License and Copyright
© 2022 by the authors; CC BY-NC-ND license
positron emission tomography; head and neck neoplasms; neovascularization; pathologic; PET/CT; urothelial carcinoma; bladder cancer; upper tract urothelial carcinoma; survival; PET; PSMA; prostate; DCFPyL; DCFBC; PSMA-1007; ovarian cancer; PET/CT; relapse; SUVmax; targeted therapy; prognosis; soft tissue sarcoma (STS); pazopanib; dynamic 18F-FDG PET/CT; SUV; two-tissue compartment model; magnetic resonance imaging; machine learning; diffusion; perfusion; texture analysis; squamous cell carcinoma of the head and neck; magnetic resonance imaging; diffusion-weighted imaging; malignant pleural mesothelioma; pleural dissemination; empyema; pleural effusion; mCRPC; SPECT/CT; Computer-assisted diagnosis; XOFIGO; Therapy response assessment; circulating miRNAs; breast cancer; imaging parameters; PET/MRI; biomarkers; triple negative breast cancer; VCAM-1; SPECT imaging; sdAbs; breast cancer; Hounsfield unit; computed tomography; prognosis; adipose tissue; precision oncology; FDG-PET/CT; PERCIST; metastatic breast cancer; prostate cancer; 18F-FACBC; PET/CT; recurrence; meta-analysis; review; meningioma; somatostatin receptor; neuroimaging; positron emission tomography; radionuclide therapy; breast; imaging; marker; radiomics; Yin Yang 1; PDAC; Mesothelin; noninvasive imaging; breast cancer; receptor status; molecular imaging; nuclear medicine; guidelines; prostate cancer; overutilization; epistemology; consensus; mantle cell lymphoma; 18F-FDG PET/CT; prognosis; Deauville criteria; Radium-223; positron emission tomography; FDG; castrate resistant prostate cancer; positron emission tomography; programmed cell death 1 receptor; diagnostic imaging; CTLA-4 Antigen; Immunotherapy; Adoptive; radioactive tracers; radionuclide imaging; CD8-Positive T-Lymphocytes; prostate cancer; PI-RADS; radiomics; magnetic resonance imaging; diffusion kurtosis imaging; dynamic contrast-enhanced magnetic resonance imaging; 68Gallium-PSMA PET/CT; prostate-specific-antigen; prostate cancer; PSA kinetics thresholds; biochemical recurrence; optimal cutoff level; non-small-cell lung cancer; circulating tumor cells; PET/CT; immunotherapy; response to treatment; PET/MRI; head and neck cancer; HPV; EBV; p16; Molecular imaging; breast cancer; miRNA expression; radiogenomics; machine learning; radiomic; diagnosis; biomarker; glioblastoma; radiation therapy; recurrence; MRI; diffusion tensor imaging; Hodgkin lymphoma; diffuse large B-cell lymphoma; positron emission tomography; staging; response assessment; locally advanced cervical cancer; PET/CT; MRI; concurrent chemoradiotherapy; treatment response; follow up; cystic tumor; International Consensus Guidelines; intraductal papillary mucinous neoplasms; pancreatic neoplasms; positron emission tomography; PET/CT; immunotherapy; PD-1; PD-L1; response to therapy; NSCLC; nuclear medicine; positron-emission tomography; single-photon emission computed tomography; immunotherapy; immune checkpoint inhibitors; gold nanoparticle; heat shock protein 70; molecular imaging; biomarker; spectral-CT; n/a